StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by Thehuntsmanon May 29, 2020 1:15pm

108 Views

Post# 31088611

RE:The comish of rubbish.

LOL. Touch skull. Pretty graphic bro.

Nailbiter1 wrote:
Haha, cherry-picking your garbage.
Labopharm fell because of FDA delay and approving competition.
Tripp wanted to merge, board members did not and kicked him out.
Company fell not because of Tripp.
FDA approved later but it was too late.

DYODD before you duh duh!

HDL scam was the lab we tested from.
Nothing to do with Genenews or Tripp.

You are sniffing the right finger buddy but you have not fully penetrated.
You are proof that feces makes a great oral lubricant.

Push that finger deeper buddy,
at some point you'll touch skull.

comissioner wrote:
He was also with and led a company from 200 mill market cap to 10 before it being sold for 20. He's also listed on the Panama papers wiki leaks along with his wife Take a look at all the subsidiarys and companies without operations that he has given shares to over the years. Combined with the extreme market movements in share price. Results of hyped up colonsentry has resulted in 0$ sales revenue with 20 million cash burn over the years. There is more reason to be pessimistic based on past performance than optimistic. This is not a good investment. Company is not undervalued. There's no way to put a 16 million valuation on this company currently. 0 revenue. Major cash burn. Will they even be able to raise financing via shares? If covid testing doesn't generate working capital this company has as much probability of delisting and being worth 0 as it does going to the targets you suggest.